Results 151 to 160 of about 306,666 (265)

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

GNL3 Orchestrates AR Transcriptional Programs to Drive Castration‐Resistant Prostate Cancer and Immune Evasion

Advanced Science, EarlyView.
GNL3 is a novel AR coregulator with dual coactivator and corepressor functions in prostate cancer (PCa). Our study uncovers a previously unrecognized mechanism by which the AR transcriptional complex integrates oncogenic signaling and immune suppression.
Cuiting Zhang, Tin Long Cheong, Nitin Narwade, Dandan Dong, Mokan Deng, Zhengqiang Miao, Zhaoqiang Ding, Wenchao Li, Kate Man Kei Lei, Gong‐Hong Wei, Terence Chuen Wai Poon, Chu‐Xia Deng, Edwin Cheung   +12 more
wiley   +1 more source

PO:25:079 | Anifrolumab in refractory dermatomyositis: a case report

Reumatismo
Background. Dermatomyositis is a rare autoimmune disease characterized by multisystem involvement. Treatment can be challenging, particularly in refractory cases unresponsive to conventional therapies, for which standardized management protocols are ...
Società Italiana di Reumatologia
doaj  

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

Advanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen, Di Lu, Rukang Liang, Weikeng Tan, Erming Zhao, Sihuang Wu, Xintong Li, Yulong Song, Miaojian Wan, Xiaoyuan Xie, Qi Zhang, Qiuli Liu   +11 more
wiley   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

Non‐Targeting shRNA‐Encoded Plasmid DNA Enhances Protective Immunity Through RIDD‐RIG‐I Signaling Pathway in the Zika Virus Animal Model

Advanced Science, EarlyView.
We present a novel DNA vaccine platform featuring intrinsic, non‐targeting dsRNA that significantly enhances immune responses by activating the regulated IRE1‐dependent decay‐RIG‐I signaling pathway. This research elucidates a previously uncharacterized mechanism for dsRNA‐mediated innate immune activation.
Min‐Syuan Huang, Hung‐Chun Liao, Po Peng, Wan‐Ling Wu, Kit Man Chai, Mei‐Yu Chen, Guann‐Yi Yu, Tsung‐Hsien Chuang, Hsin‐Wei Chen, Chuang‐Rung Chang, Shih‐Jen Liu   +10 more
wiley   +1 more source

Differential antiviral effects and immune responses in nasal and airway organoid during RSV infection: implications for interferon therapy. [PDF]

Front Immunol
Wang L, Chen L, Yang L, Hu Y, Lu D, Duan Y, Qiu L, Li Y, Zhang R, Liu H, Yang W.   +10 more
europepmc   +1 more source

Hypofractionated Radiotherapy Induces ISG15+MHC‐I+ Neutrophils to Augment Anti‐Tumor Immunity and Prime Immune Checkpoint Blockade Responses in Rectal Cancer

Advanced Science, EarlyView.
ABSTRACT Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how ...
Lichao Liu, Haihong Wang, Mingjie Li, Qian Xu, Linlin Zheng, Chaoqun Han, Zhenwei Zou, Jinghua Ren, Xiaorong Dong, Peng Zhang, Kaixiong Tao, Zhenyu Lin, Tao Zhang   +12 more
wiley   +1 more source